Email Alert | RSS

Journal of Peking University (Health Sciences) ›› 2021, Vol. 53 ›› Issue (5): 921-927. doi: 10.19723/j.issn.1671-167X.2021.05.018

Previous Articles     Next Articles

Relationship between marked hyperferritinemia and hemophagocytic lymphohistiocytosis

GAO Wei-bo,SHI Mao-jing,ZHANG Hai-yan,WU Chun-bo(),ZHU Ji-hong   

  1. Department of Emergency, Peking University People’s Hospital, Beijing 100044, China
  • Received:2019-11-30 Online:2021-10-18 Published:2021-10-11
  • Contact: Chun-bo WU E-mail:wuchunbowcb@163.com

RICH HTML

 5   

PDF (PC)

268

Abstract:

Objective: To investigate the relationship between marked hyperferritinemia (MHF) and hemophagocytic lymphohistiocytosis(HLH). Methods: The clinical data of 123 patients with MHF admitted to Peking University People’s Hospital from January 2017 to September 2018 were collected, including demographics, baseline characteristics, signs and symptoms, blood routine, blood biochemistry, coagulation function parameters, such as prothrombin time (PT), activated partial thromboplastin time (APTT), fibrinogen (Fib), d-dimer (D-D), fibrin degradation product (FDP), blood ferritin, natural killer (NK) cell activity, soluble interleukin (IL)-2 receptor and bone marrow examination. According to the diagnosis of HLH, the patients were divided into HLH group and non HLH group. The patients were divided into death group and survival group according to the 3-month follow-up results. The groups were compared and statistically analyzed. Results: In the 123 patients with MHF, the average age was (44.2±17.4) years with a male/female ratio of 1.3 ∶1. The most common causes were hematolo-gic malignancies, rheumatologic and inflammatory disorders, iron overload, and HLH. HLH was enriched as the ferritin increased, and the HLH ratios were 28.8%, 40.0%, 54.5%, 50.0%, 50.0% in ferritin value of 10 000-19 999, 20 000-29 999, 30 000-39 999, 40 000-49 999 μg/L,more than 50 000 μg/L respectively. There were 46 cases of HLH, among which 15 cases were secondary to malignancies,14 cases secondary to rheumatologic disorders, 2 cases secondary to infection, and 15 cases with no clear precipitating cause. There were significant differences between the HLH group and non-HLH group in hepatomegaly, splenomegaly, lymphadenectasis, albumin (ALB), fibrinogen(Fib), P<0.05, and no significant differences in age, gender, fever, disturbance of consciousness, ferritin level on presentation, maximum ferritin level, cytopenia in 2 or more cell lines, alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin (TBIL), direct bilirubin (DBIL), triglyceride (TG), coagulation parameters (PT, APTT, D-D, FDP, exception of Fib), and mortality rate (P>0.05). There were significant differences between the death group and survival group in disturbance of consciousness, platelet count, PT, TBIL, and DBIL (P<0.05), but no significant differences in age, gender, fever, hepatomegaly, splenomegaly, lymphadenectasis, ferritin level on presentation, maximum ferritin level, neutrophils, hemoglobin, ALT, AST, ALB, TG, coagulation parameters (Fib, APTT, D-D, FDP, exception of PT) and the HLH ratio (P>0.05). Conclusion: HLH was enriched as the ferritin increased, but marked hyperferritinemia was not specific for HLH in adults.

Key words: Hyperferritinemia, Hemophagocytic lymphohistiocytosis, Prognosis

CLC Number: 

  • R557.4

Table 1

Clinical manifestations of 123 patients with marked hyperferritinemia"

Clinical symptoms and signs Proportion of total cases,n (%) HLH,n (%)
Fever 100 (81.3) 38(38.0)
Splenomegaly 51 (41.5) 29(56.9)
Hepatomegaly 22 (17.9) 15(68.2)
Lymphadenopathy 53 (43.1) 29(54.7)
Disturbance of consciousness 16 (13.0) 6(37.5)
Hemocytopenia (more than 2 lines) 40 (32.5) 14(35.0)
Neu(<1.0×109/L) 25 (20.3) 8(32.0)
Hb(<90 g/L) 49 (39.8) 19(38.8)
PLT(<100×109/L) 86 (69.9) 33(38.4)
Hypertriglyceridemia (≥3.0 mmol/L) 38 (30.9) 17(44.7)
Low fibrinogen (≤1.5 g/L) 25 (20.3) 16(64.0)

Table 2

HLH rate of 5 groups with marked hyperferritinemia"

Ferritin n HLH, n (%)
10 000-19 999/(μg/L) 66 19 (28.8)
20 000-29 999/(μg/L) 20 8 (40.0)
30 000-39 999/(μg/L) 11 6 (54.5)
40 000-49 999/(μg/L) 10 5 (50.0)
≥50 000/(μg/L) 16 8 (50.0)

Table 3

Comparison of clinical characteristics between HLH group and non-HLH group"

Items HLH (n=46) Non-HLH (n=77) P
Age/years, M (P25, P75) 48 (31, 61) 41 (27, 56) 0.178
Male/female, n 22/24 47/30 0.153
Fever, n (%) 38 (82.6) 62 (80.5) 0.774
Splenomegaly, n (%) 29 (63.0) 22 (28.6) 0.000
Hepatomegaly, n (%) 15 (32.6) 7 (9.1) 0.001
Lymphadenopathy, n (%) 29 (63.0) 24 (31.2) 0.001
Disturbance of consciousness, n (%) 6 (13.0) 10 (13.0) 0.993
Initial ferritin/(μg/L), M (P25, P75) 12 558 (6 249, 22 407) 13 901 (10 463, 24 059) 0.386
Ferritin MAX/(μg/L), M (P25, P75) 24 816 (13 528, 41 885) 16 774 (11 909, 29 421) 0.075
WBC/(×109/L), M (P25, P75) 4.6 (2.2, 8.9) 4.3 (2.6, 9.9) 0.824
Neu /(×109/L), M (P25, P75) 3.2 (1.4, 6.6) 2.9 (1.3, 7.7) 0.913
Hb/(g/L), x ?±s 95.8±23.0 96.2±26.8 0.924
PLT/(×109/L), M (P25, P75) 52 (24, 109) 38 (18, 140) 0.453
ALT/(U/L), M (P25, P75) 78 (33, 191) 58 (25, 251) 0.960
AST/(U/L), M (P25, P75) 94 (50, 216) 63 (33, 195) 0.099
LDH/(U/L), M (P25, P75) 779 (505, 1 432) 455 (296, 805) 0.003
ALB/(g/L), x ?±s 29.7±6.6 33.9±6.2 0.001
TG/(mmol/L), M (P25, P75) 2.6 (1.4, 4.1) 2.2 (1.4, 3.2) 0.216
TBIL/(mmol/L), M (P25, P75) 14.0 (10.3, 66.5) 13.3 (9.0, 25.2) 0.387
DBIL/(mmol/L), M (P25, P75) 6.8 (3.1, 47.2) 5.8 (3.1, 14.6) 0.347
Fib/(g/L), M (P25, P75) 2.01 (1.33, 3.65) 2.79 (1.91, 3.62) 0.011
D-D/(μg/L), M (P25, P75) 2247 (853, 5 761) 812 (257, 3 027) 0.002
FDP/(mg/L), M (P25, P75) 19.0 (7.9, 50.3) 7.7 (2.5, 24.0) 0.002
PT/s, M (P25, P75) 12.4 (10.8, 14.7) 12.2 (11.3, 14.0) 0.647
APTT/s, M (P25, P75) 33.2 (29.0, 40.8) 30.9 (28.0, 35.9) 0.044
Mortality, n (%) 7 (15.2) 10 (13.0) 0.729

Table 4

Comparison of clinical characteristics between death and survival group"

Items Death group (n=17) Survival group (n=106) P
Age/years, M (P25, P75) 57 (30, 75) 44 (29, 56) 0.101
Male/female, n 11/6 58/48 0.441
Fever, n (%) 15 (88.2) 85 (80.2) 0.649
Splenomegaly, n (%) 8 (47.1) 43 (40.6) 0.614
Hepatomegaly, n (%) 5 (29.4) 17 (16.0) 0.320
Lymphadenopathy, n (%) 8 (47.1) 45 (42.5) 0.722
Disturbance of consciousness, n (%) 8 (47.1) 8 (7.5) 0.000
Initial ferritin/(μg/L), M (P25, P75) 11 225 (2 648, 28 526) 13 801(10 209, 22 242) 0.638
Ferritin MAX/(μg/L), M (P25, P75) 22 349 (13 621, 39 473) 18 177 (12 601, 34 026) 0.501
WBC/(×109/L), M (P25, P75) 4.6 (1.1, 15.1) 4.6 (2.7, 8.6) 0.814
Neu /(×109/L), M (P25, P75) 3.3 (0.6, 6.9) 3.2 (1.6, 6.2) 0.981
Hb/(g/L), x ?±s 87.8±22.0 96.4±24.9 0.116
PLT/(×109/L), M (P25, P75) 26 (13, 38) 67 (23, 165) 0.013
ALT/(U/L), M (P25, P75) 68 (27, 252) 56 (26, 162) 0.648
AST/(U/L), M (P25, P75) 117 (39, 642) 65 (36, 151) 0.290
LDH/(U/L), M (P25, P75) 714 (244, 2 479) 492 (294, 761) 0.183
ALB/(g/L), x ?±s 30.6±5.8 32.8±6.7 0.230
TG/(mmol/L), M (P25, P75) 2.2 (1.1, 3.5) 2.4 (1.4, 4.4) 0.199
TBIL/(mmol/L), M (P25, P75) 27.8 (12.2, 111.8) 12.6 (8.4, 27.2) 0.045
DBIL/(mmol/L), M (P25, P75) 17.3 (6.7, 71.3) 5.2 (2.7, 14.8) 0.017
Fib/(g/L), M (P25, P75) 2.34 (1.49, 3.69) 2.57 (1.85, 3.48) 0.504
D-D/(μg/L), M (P25, P75) 1 615 (167, 4 067) 848 (308, 3 146) 0.889
FDP/(mg/L), M (P25, P75) 11.2 (3.8, 32.0) 7.7 (2.8, 23.1) 0.665
PT/s, x ?±s 14.6±3.6 12.6±2.5 0.046
APTT/s, x ?±s 39.2±14.5 32.0±6.2 0.069
HLH ratio, n (%) 7 (41.2) 39 (36.8) 0.729
[1] Alkhateeb AA, Connor JR. The significance of ferritin in cancer: Anti-oxidation, inflammation and tumorigenesis [J]. Biochim Biophys Acta, 2013, 1836(2):245-254.
doi: 10.1016/j.bbcan.2013.07.002 pmid: 23891969
[2] Moore C, Ormseth M, Fuchs H. Causes and significance of markedly elevated serum ferritin levels in an academic medical center [J]. J Clin Rhuematol, 2013, 19(6):324-328.
[3] Crook MA, Walker PLC. Extreme hyperferritinaemia: Clinical causes [J]. J Clin Pathol, 2013, 66(5):438-440.
doi: 10.1136/jclinpath-2012-201090
[4] Sackett K, Cunderlik M, Sahni N, et al. Extreme hyperferritinemia: Causes and impact on diagnostic reasoning [J]. Am J Clin Pathol, 2016, 145(5):646-650.
doi: 10.1093/ajcp/aqw053 pmid: 27247369
[5] Otrock ZK, Hock KG, Riley SB, et al. Elevated serum ferritin is not specific for hemophagocytic lymphohistiocytosis [J]. Ann Hematol, 2017, 96(10):1667-1672.
doi: 10.1007/s00277-017-3072-0 pmid: 28762079
[6] Allen CE, Yu X, Kozinetz CA, et al. Highly elevated ferritin levels and the diagnosis of hemophagocytic lymphohistiocytosis [J]. Pediatr Blood Cancer, 2008, 50(6):1227-1235.
pmid: 18085676
[7] Zandman-Goddard G, Shoenfeld Y. Hyperferritinemia in autoimmunity [J]. Isr Med Assoc J, 2008, 10(1):83-84.
pmid: 18300583
[8] Zandman-Goddard G, Orbach H, Agmon-Levin N, et al. Hyperferritinemia is associated with serologic antiphospholipid syndrome in SLE patients [J]. Clin Rev Allergy Immunol, 2013, 44(1):23-30.
doi: 10.1007/s12016-011-8264-0
[9] Rosário C, Zandman-Goddard G, Meyron-Holtz EG, et al. The hyperferritinemic syndrome: Macrophage activation syndrome, Still’s disease, septic shock and catastrophic antiphospholipid syndrome [J]. BMC Med, 2013, 11:185.
doi: 10.1186/1741-7015-11-185
[10] Evensen KJ, Swaak TJG, Nossent JC. Increased ferritin response in adult Still’s disease: Specificity and relationship to outcome [J]. Scand J Rheumatol, 2007, 36(2):107-110.
pmid: 17476616
[11] Lee MH, Means RT Jr. Extremely elevated serum ferritin levels in a university hospital: Associated diseases and clinical significance [J]. Am J Med, 1995, 98(6):566-571.
pmid: 7778572
[12] Orbach H, Zandman-Goddard G, Amital H, et al. Novel bio-markers in autoimmune diseases: Prolactin, ferritin, vitamin D, and TPA levels in autoimmune diseases [J]. Ann N Y Acad Sci, 2007, 1109:385-400.
doi: 10.1196/annals.1398.044
[13] Agmon-Levin N, Rosário C, Katz BSP, et al. Ferritin in the antiphospholipid syndrome and its catastrophic variant (cAPS) [J]. Lupus, 2013, 22(13):1327-1335.
doi: 10.1177/0961203313504633 pmid: 24036580
[14] Wang W, Knovich MA, Coffman LG, et al. Serum ferritin: Past, present and future [J]. Biochem Biophys Acta, 2010, 1800(8):760-769.
[15] Crook MA. Hyperferritinaemia: Laboratory implications [J]. Ann Clin Biochem, 2012, 49(Pt 3):211-213.
doi: 10.1258/acb.2012.012059 pmid: 22550325
[16] Kernan KF, Carcillo JA. Hyperferritinemia and inflammation [J]. Int Immumol, 2017, 29(9):401-409.
[17] Tothova Z, Berliner N. hemophagocytic syndrome and critical illness: New insights into diagnosis and management [J]. J Intensive Care Med, 2015, 30(7):401-412.
doi: 10.1177/0885066613517076 pmid: 24407034
[18] Chandrakasan S, Filipovich AH. Hemophagocytic lymphohistiocytosis: Advances in pathophysiology, diagnosis, and treatment [J]. J Pediatr, 2013, 163(5):1253-1259.
doi: 10.1016/j.jpeds.2013.06.053
[19] Jordan MB, Allen CE, Weitzman S, et al. How I treat hemo-phagocytic lymphohistiocytosis [J]. Blood, 2011, 118(15):4041-4052.
[20] Henter JI, Elinder G, Ost A. The FHL Study Group of the Histiocyte Society. Diagnostic guidelines for hemophagocytic lymphohistiocytosis [J]. Semin Oncol, 1991, 18(1):29-33.
pmid: 1992521
[21] Henter JI, Samuelsson-Horne A, Aricò M, et al. Histocyte Society. Treatment of hemophagocytic lymphohistiocytosis with HLH-94 immunochemotherapy and bone marrow transplantation [J]. Blood, 2002, 100(7):2367-2373.
doi: 10.1182/blood-2002-01-0172
[22] Henter JI, Samuelsson-Horne A, Aricò M, et al. HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis [J]. Pediatr Blood Cancer, 2007, 48(2):124-131.
doi: 10.1002/(ISSN)1545-5017
[23] Janka GE, Lehmberg K. Hemophagocytic syndromes-an update [J]. Blood Rev, 2014, 28(4):135-142.
doi: 10.1016/j.blre.2014.03.002
[24] Senjo H, Higuchi T, Okada S, et al. Hyperferritinemia: Causes and significance in a general hospital [J]. Hematology, 2018, 23(10):817-822.
doi: 10.1080/10245332.2018.1488569
[25] Kaito K, Kobayashi M, Katayama T, et al. Prognostic factors of hemophagocytic syndrome in adults: analysis of 34 cases [J]. Eur J Haematol, 1997, 59(4):247-253.
pmid: 9338623
[26] Janka GE, Schneider EM. Modern management of children with haemophagocytic Lymphohistiocytosis [J]. Br J Haematol, 2004, 124(1):4-14.
doi: 10.1046/j.1365-2141.2003.04726.x
[27] 金志丽, 王旖旎, 胡亮钉, 等. 血清铁蛋白升高在成人噬血细胞综合征诊断中的作用 [J]. 临床血液学杂志, 2016, 29(9):717-720.
[28] Schram AM, Campigotto F, Mullally A, et al. Marked hyperferritinemia does not predict for HLH in the adult population [J]. Blood, 2015, 125(10):1548-1552.
doi: 10.1182/blood-2014-10-602607
[1] Fei WANG,Xiang ZHU,Bei HE,Hong ZHU,Ning SHEN. Spontaneous remission of follicular bronchiolitis with nonspecific interstitial pneumonia: A case report and literature review [J]. Journal of Peking University (Health Sciences), 2021, 53(6): 1196-1200.
[2] Mei-xiang ZHANG,Wen-zhi SHI,Jian-xin LIU,Chun-jian WANG,Yan LI,Wei WANG,Bin JIANG. Clinical characteristics and prognosis of MLL-AF6 positive patients with acute myeloid leukemia [J]. Journal of Peking University (Health Sciences), 2021, 53(5): 915-920.
[3] Yan-fang JIANG,Jian WANG,Yong-jian WANG,Jia LIU,Yin PEI,Xiao-peng LIU,Ying-fang AO,Yong MA. Mid-to-long term clinical outcomes and predictors after anterior cruciate ligament revision [J]. Journal of Peking University (Health Sciences), 2021, 53(5): 857-863.
[4] XIAO Ruo-tao,LIU Cheng,XU Chu-xiao,HE Wei,MA Lu-lin. Prognostic value of preoperative platelet parameters in locally advanced renal cell carcinoma [J]. Journal of Peking University (Health Sciences), 2021, 53(4): 647-652.
[5] YU Yan-fei,HE Shi-ming,WU Yu-cai,XIONG Sheng-wei,SHEN Qi,LI Yan-yan,YANG Feng,HE Qun,LI Xue-song. Clinicopathological features and prognosis of fumarate hydratase deficient renal cell carcinoma [J]. Journal of Peking University (Health Sciences), 2021, 53(4): 640-646.
[6] ZHAO Xun,YAN Ye,HUANG Xiao-juan,DONG Jing-han,LIU Zhuo,ZHANG Hong-xian,LIU Cheng,MA Lu-lin. Influence of deep invasive tumor thrombus on the surgical treatment and prognosis of patients with non-metastatic renal cell carcinoma complicated with venous tumor thrombus [J]. Journal of Peking University (Health Sciences), 2021, 53(4): 665-670.
[7] CHEN Huai-an,LIU Shuo,LI Xiu-jun,WANG Zhe,ZHANG Chao,LI Feng-qi,MIAO Wen-long. Clinical value of inflammatory biomarkers in predicting prognosis of patients with ureteral urothelial carcinoma [J]. Journal of Peking University (Health Sciences), 2021, 53(2): 302-307.
[8] Shi-bo LIU,Hui GAO,Yuan-chun FENG,Jing LI,Tong ZHANG,Li WAN,Yan-ying LIU,Sheng-guang LI,Cheng-hua LUO,Xue-wu ZHANG. Clinical features of hydronephrosis induced by retroperitoneal fibrosis: 17 cases reports [J]. Journal of Peking University (Health Sciences), 2020, 52(6): 1069-1074.
[9] Wei-qian CHEN,Xiao-na DAI,Ye YU,Qin WANG,Jun-yu LIANG,Yi-ni KE,Cai-hong YI,Jin LIN. Analysis of clinical features and prognosis in patients with primary Sjögren’s syndrome and autoimmune liver disease [J]. Journal of Peking University (Health Sciences), 2020, 52(5): 886-891.
[10] Ru MA,Xin-bao LI,Feng-cai YAN,Yu-lin LIN,Yan LI. Clinical evaluation of tumor-stroma ratio in pseudomyxoma peritonei from the appendix [J]. Journal of Peking University (Health Sciences), 2020, 52(2): 240-246.
[11] Wen-peng WANG,Jie-fu WANG,Jun HU,Jun-feng WANG,Jia LIU,Da-lu KONG,Jian LI. Clinicopathological features and prognosis of colorectal stromal tumor [J]. Journal of Peking University (Health Sciences), 2020, 52(2): 353-361.
[12] Xiao WANG,Zhao-xing LI,Huan-fang FAN,Li-ying WEI,Xu-jin GUO,Na GUO,Tong WANG. A rare case of cystadenoma in the small intestine [J]. Journal of Peking University (Health Sciences), 2020, 52(2): 382-384.
[13] Yu-qing OUYANG,Lian-fang NI,Xin-min LIU. Prognosis factors analysis of patients with malignant solitary pulmonary nodules [J]. Journal of Peking University(Health Sciences), 2020, 52(1): 158-162.
[14] Yan-jin WANG,Xiao-yan XIE,Ying-ying HONG,Jia-ying BAI,Jian-yun ZHANG,Tie-jun LI. Clinicopathological analysis of 844 cases of odontogenic keratocysts [J]. Journal of Peking University(Health Sciences), 2020, 52(1): 35-42.
[15] Jian-jun SUN,Jun YANG,Jing-cheng XIE,Qing CHANG,Chang-cheng MA,Mei ZHENG,Hung-I LIAO,Tao WANG,Xiao-dong CHEN,Yun-feng HAN,Guo-zhong LIN,Tao YU,Jia ZHANG,Yu SI. Comparative clinical study on seldom segment with multiple segment intramedullary primary spinal cord tumors [J]. Journal of Peking University(Health Sciences), 2019, 51(5): 840-850.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
[1] Author. English Title Test[J]. Journal of Peking University(Health Sciences), 2010, 42(1): 1 -10 .
[2] . [J]. Journal of Peking University(Health Sciences), 2009, 41(2): 188 -191 .
[3] . [J]. Journal of Peking University(Health Sciences), 2009, 41(3): 376 -379 .
[4] . [J]. Journal of Peking University(Health Sciences), 2009, 41(4): 459 -462 .
[5] . [J]. Journal of Peking University(Health Sciences), 2007, 39(3): 319 -322 .
[6] . [J]. Journal of Peking University(Health Sciences), 2007, 39(3): 333 -336 .
[7] . [J]. Journal of Peking University(Health Sciences), 2007, 39(3): 337 -340 .
[8] . [J]. Journal of Peking University(Health Sciences), 2007, 39(3): 225 -328 .
[9] . [J]. Journal of Peking University(Health Sciences), 2007, 39(4): 346 -350 .
[10] . [J]. Journal of Peking University(Health Sciences), 2007, 39(4): 369 -373 .
Copyright © Journal of Peking University (Health Sciences), All Rights Reserved.
Powered by Beijing Magtech Co. Ltd